HRP20020004A2 - Method for the preparation of pure citalopram - Google Patents
Method for the preparation of pure citalopram Download PDFInfo
- Publication number
- HRP20020004A2 HRP20020004A2 HR20020004A HRP20020004A HRP20020004A2 HR P20020004 A2 HRP20020004 A2 HR P20020004A2 HR 20020004 A HR20020004 A HR 20020004A HR P20020004 A HRP20020004 A HR P20020004A HR P20020004 A2 HRP20020004 A2 HR P20020004A2
- Authority
- HR
- Croatia
- Prior art keywords
- amide
- cyanide
- citalopram
- group
- reaction
- Prior art date
Links
- 229960001653 citalopram Drugs 0.000 title claims description 40
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 title claims description 39
- 238000000034 method Methods 0.000 title claims description 29
- 238000002360 preparation method Methods 0.000 title claims description 8
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 150000001408 amides Chemical class 0.000 claims description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 14
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 11
- 239000000460 chlorine Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 239000011541 reaction mixture Substances 0.000 claims description 7
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 229910052763 palladium Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical group 0.000 claims description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 2
- 239000012346 acetyl chloride Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 150000001263 acyl chlorides Chemical class 0.000 claims 1
- 150000001266 acyl halides Chemical class 0.000 claims 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000002585 base Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 9
- -1 5-thiazolinyl group Chemical group 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 4
- PTJADDMMFYXMMG-UHFFFAOYSA-N Demethylcitalopram Chemical class O1CC2=CC(C#N)=CC=C2C1(CCCNC)C1=CC=C(F)C=C1 PTJADDMMFYXMMG-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- WOLPGGGWZDXCNM-UHFFFAOYSA-N 3-[5-bromo-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]-n,n-dimethylpropan-1-amine Chemical compound O1CC2=CC(Br)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WOLPGGGWZDXCNM-UHFFFAOYSA-N 0.000 description 1
- CLMSHAWYULIVFQ-UHFFFAOYSA-N 3-bromo-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(Br)OC(=O)C2=C1 CLMSHAWYULIVFQ-UHFFFAOYSA-N 0.000 description 1
- GHZPDRVHYHFILK-UHFFFAOYSA-N 3-chloro-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(Cl)OC(=O)C2=C1 GHZPDRVHYHFILK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical compound [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200001929 | 2000-12-22 | ||
| PCT/DK2001/000147 WO2001045483A2 (en) | 2000-12-22 | 2001-03-07 | Method for the preparation of pure citalopram |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20020004A2 true HRP20020004A2 (en) | 2003-04-30 |
Family
ID=8159922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20020004A HRP20020004A2 (en) | 2000-12-22 | 2002-01-04 | Method for the preparation of pure citalopram |
Country Status (43)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR022329A1 (es) | 1999-01-29 | 2002-09-04 | Lundbeck & Co As H | Metodo para la preparacion de 5-cianoftalida |
| CN1142926C (zh) * | 1999-04-14 | 2004-03-24 | H·隆德贝克有限公司 | 制备西酞普兰的方法 |
| ITMI991581A1 (it) * | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
| ITMI991579A1 (it) | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
| EP1228056B1 (en) | 1999-10-25 | 2004-09-22 | H. Lundbeck A/S | Method for the preparation of citalopram |
| PT1246812E (pt) | 1999-12-28 | 2004-08-31 | Lundbeck & Co As H | Metodo para a preparacao de citalopram |
| EP1246813B1 (en) | 1999-12-30 | 2003-11-05 | H. Lundbeck A/S | Method for the preparation of citalopram |
| ATE252570T1 (de) | 2000-01-14 | 2003-11-15 | Lundbeck & Co As H | Verfahren zur herstellung von 5-cyanophthalid |
| NL1017417C1 (nl) | 2000-03-03 | 2001-03-16 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
| NZ521201A (en) | 2000-03-13 | 2004-02-27 | H | Method for the preparation of citalopram |
| EP1265881A1 (en) | 2000-03-13 | 2002-12-18 | H. Lundbeck A/S | Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| IES20010206A2 (en) | 2000-03-13 | 2002-03-06 | Lundbeck & Co As H | Method for the preparation of citalopram |
| IL151488A0 (en) | 2000-03-14 | 2003-04-10 | Lundbeck & Co As H | Method for the preparation of citalopram |
| EA200200982A1 (ru) * | 2000-03-16 | 2003-02-27 | Х.Лундбекк А/С | Способ получения 5-циано-1-(4-фторфенил)-1,3-дигидроизобензофуранов |
| AR032455A1 (es) | 2000-05-12 | 2003-11-12 | Lundbeck & Co As H | Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva |
| IL144816A (en) | 2000-08-18 | 2005-09-25 | Lundbeck & Co As H | Method for the preparation of citalopram |
| PT1181272E (pt) | 2000-12-28 | 2003-01-31 | Lundbeck & Co As H | Processo para a preparacao de citalopram puro |
| GB0105627D0 (en) * | 2001-03-07 | 2001-04-25 | Cipla Ltd | Preparation of phthalanes |
| HUP0400095A3 (en) * | 2001-03-09 | 2005-10-28 | Ranbaxy Lab Ltd | Process for the preparation of citalopram |
| US6967259B2 (en) * | 2001-09-24 | 2005-11-22 | Pharmachem Technologies Limited | Process for the preparation of Citalopram intermediate |
| KR20050043776A (ko) * | 2001-11-08 | 2005-05-11 | 세프라코 아이엔시. | 거울상 이성질체로 농축된, 시탈로프람의 데스메틸 및디데스메틸 대사물을 이용한 우울증 및 다른 중추신경계질환 치료방법 |
| AU2003222435A1 (en) * | 2002-01-07 | 2003-07-24 | Sun Pharmaceutical Industries Limited | Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile |
| GB0204607D0 (en) * | 2002-02-27 | 2002-04-10 | Matrix Lab Ltd | Process |
| MXPA05005155A (es) * | 2002-11-15 | 2005-07-22 | Akzo Nobel Nv | Tratamiento de purificacion/decoloracion para nitrilos grasos. |
| TR200504022T1 (tr) * | 2003-03-24 | 2006-08-21 | Hetero Drugs Limited | (S)-sitalopram oksalatın yeni sıvı kristal formları. |
| US7019153B2 (en) * | 2003-06-10 | 2006-03-28 | Sun Pharmaceutical Industries Limited | Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid |
| BR0318581A (pt) * | 2003-10-28 | 2006-10-10 | Wockhardt Ltd | processo melhorando para fabriacação de bromidrato de citalopram |
| CN100569765C (zh) | 2003-12-19 | 2009-12-16 | 杭州民生药业集团有限公司 | 西酞普兰中间体晶体碱 |
| TWI358407B (en) * | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
| CN114763343A (zh) * | 2021-01-14 | 2022-07-19 | 浙江华海药业股份有限公司 | 一种西酞普兰或s-西酞普兰的纯化方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE536169C (de) * | 1926-08-21 | 1931-10-20 | British Dyestuffs Corp Ltd | Verfahren zur Gewinnung von tertiaeren aromatischen Aminen aus ihren Gemischen mit sekundaeren und primaeren aromatischen Aminen |
| US1992111A (en) * | 1931-06-20 | 1935-02-19 | Du Pont | Separation of secondary and tertiary amines |
| DE1032261B (de) * | 1955-03-08 | 1958-06-19 | Leda Chemicals Ltd | Verfahren zur Abtrennung sekundaerer Amine aus einer primaeres und sekundaeres Amin enthaltenden Mischung |
| GB1143702A (ja) | 1965-03-18 | |||
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4302399A (en) * | 1978-09-28 | 1981-11-24 | Dynapol | Acetylation of crude reaction products containing polymeric colorants |
| GB8419963D0 (en) | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| US4943591A (en) | 1984-10-17 | 1990-07-24 | Glaxo Group Limited | Dichloroaniline derivatives |
| DE3926765A1 (de) * | 1989-08-12 | 1991-02-14 | Hoechst Ag | Verfahren zur verminderung von primaerem und sekundaerem amin in einem tertiaeren amin |
| US5296507A (en) | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
| DK213290D0 (da) * | 1990-09-06 | 1990-09-06 | Lundbeck & Co As H | Treatment of cerebrovascular disorders |
| DE19626659A1 (de) | 1996-07-03 | 1998-01-08 | Basf Ag | Verfahren zur Herstellung von Phthaliden |
| DE19627697A1 (de) | 1996-07-10 | 1998-01-15 | Basf Ag | Verfahren zur Herstellung von Phthaliden |
| AU4655597A (en) * | 1997-06-30 | 1999-01-19 | Beloit Technologies, Inc. | Method and apparatus for the high speed application of coating to a traveling paper web |
| DE1015416T1 (de) | 1997-07-08 | 2000-10-05 | Lundbeck A S Kobenhavn Valby H | Verfahren zur herstellung von citalopram |
| UA62985C2 (en) | 1997-11-10 | 2004-01-15 | Lunnbeck As H | A method for the preparation of citalopram |
| JP3813820B2 (ja) | 1997-11-11 | 2006-08-23 | ハー・ルンドベック・アクチエゼルスカベット | シタロプラムの製造方法 |
| WO2000023431A1 (en) * | 1998-10-20 | 2000-04-27 | H. Lundbeck A/S | Method for the preparation of citalopram |
| EA003057B1 (ru) | 1998-12-23 | 2002-12-26 | Х.Лундбекк А/С | Способ получения 5-цианофталида |
| AR022329A1 (es) | 1999-01-29 | 2002-09-04 | Lundbeck & Co As H | Metodo para la preparacion de 5-cianoftalida |
| CN1142926C (zh) | 1999-04-14 | 2004-03-24 | H·隆德贝克有限公司 | 制备西酞普兰的方法 |
| ITMI991579A1 (it) * | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
| ITMI991581A1 (it) * | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | Metodo per la preparazione di citalopram |
| ITMI991486A1 (it) * | 1999-07-06 | 2001-01-06 | Vis Farmaceutici S P A | Processo per la sintesi di citalopram |
| EP1228056B1 (en) | 1999-10-25 | 2004-09-22 | H. Lundbeck A/S | Method for the preparation of citalopram |
| US6310222B1 (en) | 1999-11-01 | 2001-10-30 | Sumika Fine Chemicals Co., Ltd. | Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate |
| IES20010143A2 (en) | 2000-02-24 | 2001-07-25 | Lundbeck & Co As H | Method for the preparation of citalopram |
| NL1017415C1 (nl) | 2000-02-24 | 2001-05-18 | Lundbeck & Co As H | Werkwijze voor de bereiding van Citalopram. |
| GB0005477D0 (en) | 2000-03-07 | 2000-04-26 | Resolution Chemicals Limited | Process for the preparation of citalopram |
| GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
| IL144816A (en) | 2000-08-18 | 2005-09-25 | Lundbeck & Co As H | Method for the preparation of citalopram |
| PT1181272E (pt) | 2000-12-28 | 2003-01-31 | Lundbeck & Co As H | Processo para a preparacao de citalopram puro |
-
2001
- 2001-03-07 CA CA002360303A patent/CA2360303C/en not_active Expired - Fee Related
- 2001-03-07 SK SK1848-2001A patent/SK284428B6/sk not_active IP Right Cessation
- 2001-03-07 TR TR2002/01166T patent/TR200201166T1/xx unknown
- 2001-03-07 KR KR10-2001-7016686A patent/KR100439329B1/ko not_active IP Right Cessation
- 2001-03-07 EP EP04004482A patent/EP1462447A3/en not_active Withdrawn
- 2001-03-07 AU AU2001100405A patent/AU2001100405B4/en not_active Ceased
- 2001-03-07 IL IL147226A patent/IL147226A/en not_active IP Right Cessation
- 2001-03-07 EP EP01913726A patent/EP1181713B1/en not_active Expired - Lifetime
- 2001-03-07 SK SK4-2005A patent/SK286283B6/sk not_active IP Right Cessation
- 2001-03-07 DK DK01913726T patent/DK1181713T3/da active
- 2001-03-07 SI SI200130238T patent/SI1181713T1/xx unknown
- 2001-03-07 ES ES01913726T patent/ES2228824T3/es not_active Expired - Lifetime
- 2001-03-07 PL PL353398A patent/PL205724B1/pl not_active IP Right Cessation
- 2001-03-07 DE DE60105926T patent/DE60105926T2/de not_active Expired - Lifetime
- 2001-03-07 WO PCT/DK2001/000147 patent/WO2001045483A2/en active Application Filing
- 2001-03-07 NL NL1017525A patent/NL1017525C1/nl not_active IP Right Cessation
- 2001-03-07 BR BR0106272-7A patent/BR0106272A/pt not_active Application Discontinuation
- 2001-03-07 AU AU39201/01A patent/AU3920101A/en active Pending
- 2001-03-07 EA EA200200018A patent/EA003581B1/ru not_active IP Right Cessation
- 2001-03-07 SG SG200504030-8A patent/SG167655A1/en unknown
- 2001-03-07 JP JP2001546230A patent/JP3798982B2/ja not_active Expired - Fee Related
- 2001-03-07 MX MXPA01013151A patent/MXPA01013151A/es active IP Right Grant
- 2001-03-07 AT AT01913726T patent/ATE277920T1/de not_active IP Right Cessation
- 2001-03-07 CN CNB018011225A patent/CN1282648C/zh not_active Expired - Lifetime
- 2001-03-07 PT PT01913726T patent/PT1181713E/pt unknown
- 2001-03-09 HU HU0101029A patent/HU0101029D0/hu unknown
- 2001-03-09 IS IS5883A patent/IS2060B/xx unknown
- 2001-03-12 CZ CZ2001890A patent/CZ292200B6/cs not_active IP Right Cessation
- 2001-03-12 GB GB0105983A patent/GB2357763B/en not_active Revoked
- 2001-03-13 NO NO20011271A patent/NO20011271A/no not_active IP Right Cessation
- 2001-03-13 FI FI20010500A patent/FI108639B/fi not_active IP Right Cessation
- 2001-03-14 FR FR0103455A patent/FR2812877B1/fr not_active Expired - Fee Related
- 2001-03-15 AR ARP010101209A patent/AR030056A1/es not_active Application Discontinuation
- 2001-03-15 IE IE20010254A patent/IES20010254A2/en not_active IP Right Cessation
- 2001-03-16 GR GR20010100132A patent/GR1003874B/el not_active IP Right Cessation
- 2001-03-16 DE DE10112829A patent/DE10112829C1/de not_active Expired - Fee Related
- 2001-03-21 AT AT0020801U patent/AT4367U1/de not_active IP Right Cessation
- 2001-03-22 CH CH00545/01A patent/CH691535A5/de not_active IP Right Cessation
- 2001-03-22 IT IT2001MI000602A patent/ITMI20010602A1/it unknown
- 2001-03-22 BE BE2001/0188A patent/BE1013212A6/fr not_active IP Right Cessation
- 2001-06-22 NL NL1018360A patent/NL1018360C1/nl not_active IP Right Cessation
- 2001-06-26 BE BE2001/0435A patent/BE1013213A6/fr not_active IP Right Cessation
- 2001-07-03 UA UA2002021552A patent/UA71634C2/uk unknown
- 2001-07-05 HU HU0102817A patent/HUP0102817A3/hu unknown
- 2001-07-26 FI FI20011577A patent/FI20011577A0/fi unknown
- 2001-07-27 ES ES200101762A patent/ES2170732B2/es not_active Expired - Fee Related
- 2001-09-14 SE SE0103045A patent/SE517623C2/sv not_active IP Right Cessation
- 2001-12-10 BG BG106203A patent/BG65131B1/bg unknown
- 2001-12-11 ZA ZA200110179A patent/ZA200110179B/xx unknown
- 2001-12-20 NZ NZ516298A patent/NZ516298A/xx unknown
-
2002
- 2002-01-04 HR HR20020004A patent/HRP20020004A2/hr not_active Application Discontinuation
- 2002-01-08 US US10/046,126 patent/US6455710B1/en not_active Expired - Fee Related
-
2003
- 2003-02-10 HK HK03100966.7A patent/HK1048812B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20020004A2 (en) | Method for the preparation of pure citalopram | |
| AU2001100399A4 (en) | Process for the preparation of pure citalopram | |
| SK285528B6 (sk) | Spôsob výroby bázy citalopramu alebo soli citalopramu | |
| CA2401374A1 (en) | Method for the preparation of citalopram | |
| AU744112B1 (en) | Process for the preparation of pure citalopram | |
| DK174018B1 (da) | Proces til fjernelse af desmethyl citalopram fra et citalopram produkt | |
| GB2359811A (en) | Purification of citalopram by acylation of the methylamino group of the desmethyl citalopram impurity & subsequent removal of the ensuing amide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20100306 Year of fee payment: 10 |
|
| ODBC | Application rejected |